메뉴바로가기 본문바로가기

IP

Improving Human Wellness Through Innovative Recombinant Protein Biotechnology

Technology

InThera’s Patents for Core Technology & Platform

9 registered patents

1 newly registered patent (USA)

3 patent applications 1 KR patent & 2 PCTs

  • A Patent for norovirus VLP vaccine (RID+GII.4)
    was registered in USA.

    Feb. 28, 2023

  • The PCT application for multivalent norovirus
    VLP vaccine (mRID + Multi (penta))

    Apr. 2023

  • Enter national phase (10 countries including EU) of the PCT
    for encapsulin PNP-based vaccine platform

    (Prophylactic/Therapeutic vaccine)
Highly-efficient
soluble VLP
expression system

2016

10-2016-0106257

KR 2018602 B1

A MANUFACTURING METHOD FOR SOLUBLE AND ACTIVE RECOMBINANT PROTEIN USING Aminoacyl tRNA synthetase N-terminal domain AS FUSION PARTNER AND A PRODUCT THEREOF

2017

10-2017-0033692

KR 1915740 B1

Novel Peptide for Enhancing Expression Efficiency and Fusion Protein Including the Same

PCT/KR2017/002902

10-2017-0033689

KR 1914779 B1

Recombinant Expression Vectors for Producing Norovirus Vaccine

PCT/KR2017/002945

10-2017-0157348

KR 2014826 B1

Novel peptide for enhancing expression efficiency and fusion protein including the same

10-2018-0145450

KR10-2120335

Recombinant Expression Vectors for Producing Norovirus Vaccine

2018

10-2018-0047365

KR 2038876 B1

Novel peptides for enhancing soluble expression of target proteins

Norovirus VLP vaccine

PCT application filing in 2018. 11.23 : PCT/KR2018/014495

USA patent registration (‘23.02.28) : US 11,591,630

Modular
VLNP
Platform

2020

10-2020-0066119

KR10-2264535

RECOMBINANT EXPRESSION VECTOR FOR PRODUCTION OF ENCAPSULIN-BASED VACCINE AND METHOD FOR MANUFACTURING THE SAME (RV & HPV)

2021

2021. 05. 12

10-2021-0061143

RECOMBINANT EXPRESSION VECTOR for PRODUCTION OF ENCAPSULIN-BASED DENGUE VIRUS OR CORONA VIRUS VACCINE AND METHOD FOR PREPARING THE SAME

2023
RECOMBINANT EXPRESSION VECTOR FOR PRODUCTION OF
ENCAPSULIN-BASED VACCINE AND METHOD FOR MANUFACTURING THE SAME

PCT application filing 2021.05.31 : PCT/KR2021/006758

National Phase Entry(‘22.12)(US,AU,TH,IN,CA,EP,JP,PH,VN,ID,CN)

Application filing
Norovirus Additional mRID/ Multivalent Genotype

PCT Application filing in ‘23.04
(National Phase Entry (15 countries))

Application filing